PROQR THERAPEUTICS N.V Reports Q2 FY2023 Earnings Results on June 30, 2023
August 15, 2023
🌥️Earnings Overview
On June 30 2023, PROQR THERAPEUTICS N.V ($NASDAQ:PRQR). reported their second quarter earnings results for FY2023, with total revenue of EUR 1.2 million, a 17.6% increase from the same quarter the previous year. Net income for the period was EUR -8.0 million, a decrease from the EUR -14.9 million reported in the same quarter the year prior.
Share Price
On June 30, 2023, PROQR THERAPEUTICS N.V reported their Q2 FY2023 earnings results and the stock opened at $1.5 and closed at $1.4, representing a 3.4% decrease from the previous day’s closing price of $1.5. Despite this decline, PROQR THERAPEUTICS N.V remains one of the leading innovators in the field of rare disease therapies. PROQR THERAPEUTICS N.V is constantly engaging in research and development efforts to create novel therapies that can help improve the quality of life for patients with rare diseases. The company’s increased revenue is attributed to their investing in clinical development and research activities.
Overall, PROQR THERAPEUTICS N.V continues to be a leader in the field of rare disease therapies. The company’s commitment to developing innovative treatments has been demonstrated by its increased revenues and successful completion of clinical trials. As such, PROQR THERAPEUTICS N.V looks to be a promising investment opportunity for those looking to invest in the future of rare disease treatments. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for PRQR. More…
| Total Revenues | Net Income | Net Margin |
| 3.84 | -54.23 | -1438.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for PRQR. More…
| Operations | Investing | Financing |
| 1.18 | -0.61 | -30.89 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for PRQR. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 147.99 | 96.49 | 0.64 |
Key Ratios Snapshot
Some of the financial key ratios for PRQR are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -1172.6% |
| FCF Margin | ROE | ROA |
| 13.5% | -50.8% | -19.0% |
Analysis
GoodWhale recently conducted a comprehensive analysis of PROQR THERAPEUTICS N.V’s wellbeing. After considering financial and business elements, our Risk Rating concluded that PROQR THERAPEUTICS N.V is a medium risk investment. In more detail, our analysis identified three risk warnings in the income sheet, balance sheet, and cashflow statement. We encourage potential and existing investors to review these risks before making an investment decision. To access our in-depth risk assessment and analysis, simply register on GoodWhale.com. Our team is always available to provide additional support and answer any questions you may have. More…
Peers
It is among the leading firms in the industry and is competing with other companies such as Merus NV, Aileron Therapeutics Inc, and Vera Therapeutics Inc to develop groundbreaking therapies for patients worldwide.
– Merus NV ($NASDAQ:MRUS)
Merus NV is a biotechnology company based in the Netherlands. Founded in 2015, the company is focused on developing therapeutic antibodies for cancer and autoimmune diseases. Merus NV has a market cap of 1.03B as of 2023 and a Return on Equity (ROE) of -45.66%. This market capitalization suggests that it is a mid-sized company, as it is significantly smaller than many of its larger peers in the biotechnology sector. The company’s Return on Equity, however, is not impressive, coming in at -45.66%. This indicates that Merus NV is having difficulty generating profits from its operations.
– Aileron Therapeutics Inc ($NASDAQ:ALRN)
Aileron Therapeutics Inc is a biopharmaceutical company focused on developing novel therapies that modulate and restore healthy cellular aging processes. Based in Boston, Massachusetts, Aileron has a market capitalization of 7.04M as of 2023, indicating a relatively small size compared to its larger peers. It also shows a negative return on equity of -88.21%, suggesting that the company has yet to generate profits or return any value to shareholders. Nonetheless, Aileron continues to be an innovator in the field of cellular aging, exploring new pathways to combat age-related disease and extend healthy human life expectancy.
– Vera Therapeutics Inc ($NASDAQ:VERA)
Vera Therapeutics Inc is a biopharmaceutical company that specializes in discovering and developing novel immune-modulating therapeutics. Currently, the company has a market capitalization of 336.83 million as of 2023. This market cap indicates the size and value of the company and its potential for growth. Additionally, Vera Therapeutics Inc has a Return on Equity (ROE) of -53.43%, indicating that the company is not utilizing its shareholders’ equity efficiently. Nevertheless, Vera Therapeutics Inc is continuing to develop novel therapeutics and is looking to increase ROE in the near future.
Summary
The investing analysis of PROQR THERAPEUTICS N.V is mixed. On June 30 2023, the company reported total revenue of EUR 1.2 million, up 17.6% from the same quarter last year.
However, the reported net income was EUR -8.0 million, a decrease from the previous year’s figure of -14.9 million. This news caused stock price to drop on that day, and investors should take this into consideration before making any decisions. Nevertheless, with further development and outcomes of their research and development activities, PROQR THERAPEUTICS N.V could potentially be a strong investment prospect in the future.
Related Posts
Recent Posts
